[{"data":1,"prerenderedAt":199},["ShallowReactive",2],{"drug-iloperidone":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":50,"contraindications":92,"warnings":102,"renal":119,"monitoring":120,"interactions":121,"review":122,"examples":125,"atc":134,"iran":136,"links":143,"populations":160,"usApproval":194},"iloperidone",1,{"fa":7,"en":8},"ایلوپریدون","Iloperidone","nervous-system",{"fa":11,"en":12},"ضدروان‌پریشی آتیپیک","Atypical antipsychotic",[14],{"name":15,"market":16},"Fanapt","US",[18,19,7],"fanapt","فاناپت",[21,35,43],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-6","tablet","oral","6 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},6,"mg",false,[16],[32],{"source":33,"section":34},"fda-fanapt","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-12","12 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},12,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":47,"refs":48},"tab-1","1 mg tablet",{"amount":5,"unit":28,"perUnit":23,"scored":29},[16],[49],{"source":33,"section":34},[51,81],{"id":52,"disease":53,"label":54,"population":57,"type":61,"unit":28,"dose":62,"refs":64,"notes":67},"scz","schizophrenia",{"fa":55,"en":56},"اسکیزوفرنی بزرگسال — هدف ۶ تا ۱۲ mg دو بار در روز پس از تیتراسیون از ۱ mg دو بار","Schizophrenia, adults — target 6–12 mg twice daily after titrating from 1 mg twice daily",{"minAge":58},{"value":59,"unit":60},18,"year","fixed",{"perDose":27,"perDoseMax":39,"dosesPerDay":63},2,[65],{"source":33,"section":66},"2.1, Table 1",[68],{"text":69,"refs":72},{"fa":70,"en":71},"تیتراسیون روزانه طبق جدول ۱ (۱، ۲، ۴، ۶ mg دو بار…) برای پرهیز از افت فشار وضعیتی. وقفه بیش از ۳ روز: تیتراسیون از اول. متابولیزه‌کننده ضعیف CYP2D6 یا مهارکننده قوی CYP2D6\u002F3A4: نصف دوز.","Daily titration per Table 1 (1, 2, 4, 6 mg twice daily…) to avoid orthostatic hypotension. Off >3 days: re-titrate. CYP2D6 poor metabolisers or strong CYP2D6\u002F3A4 inhibitors: half the dose.",[73,75,77,79],{"source":33,"section":74},"2.1",{"source":33,"section":76},"2.5",{"source":33,"section":78},"2.2",{"source":33,"section":80},"2.4",{"id":82,"disease":83,"label":84,"population":87,"type":61,"unit":28,"dose":89,"refs":90},"bp","bipolar-mania",{"fa":85,"en":86},"مانیا یا دوره مختلط دوقطبی I بزرگسال — هدف ۱۲ mg دو بار پس از تیتراسیون","Bipolar I mania or mixed episodes, adults — target 12 mg twice daily after titration",{"minAge":88},{"value":59,"unit":60},{"perDose":39,"dosesPerDay":63},[91],{"source":33,"section":66},[93],{"id":94,"severity":95,"text":96,"refs":99},"hyper","block",{"fa":97,"en":98},"حساسیت شناخته‌شده به ایلوپریدون.","Known hypersensitivity to iloperidone.",[100],{"source":33,"section":101},"4",[103,110],{"text":104,"refs":107},{"fa":105,"en":106},"هشدار جعبه‌ای: افزایش مرگ در سالمندان مبتلا به سایکوز ناشی از دمانس — برای این کاربرد تأیید نشده.","Boxed warning: increased mortality in elderly patients with dementia-related psychosis — not approved for this use.",[108],{"source":33,"section":109},"Boxed Warning",{"text":111,"refs":114},{"fa":112,"en":113},"طولانی شدن QT؛ افت فشار وضعیتی و سنکوپ؛ NMS؛ دیسکینزی دیررس؛ تغییرات متابولیک؛ لکوپنی؛ پریاپیسم. نارسایی شدید کبد توصیه نمی‌شود.","QT prolongation; orthostatic hypotension and syncope; NMS; tardive dyskinesia; metabolic changes; leukopenia; priapism. Not recommended in severe hepatic impairment.",[115,117],{"source":33,"section":116},"5",{"source":33,"section":118},"2.3",[],[],[],{"status":123,"reviewer":124,"date":124},"unverified",null,[126,131],{"regimen":52,"formulation":22,"input":127,"expect":130},{"ageYears":128,"weightKg":129},30,70,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":39},{"regimen":82,"formulation":36,"input":132,"expect":133},{"ageYears":128,"weightKg":129},{"perDose":39,"tabletsPerDoseRounded":5},[135],"N05AX14",{"status":137,"refs":138},"not-found",[139],{"source":140,"section":141,"url":142},"darooyab-generic","G-4919\u002FIloperidone","https:\u002F\u002Fwww.darooyab.ir\u002FG-4919\u002FIloperidone",[144,148,152,155,158],{"kind":145,"url":146,"label":147},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022192","NDA022192",{"kind":149,"url":150,"label":151},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b","FDA Fanapt",{"kind":153,"url":154,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa609026.html",{"kind":156,"url":157,"label":135},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N05AX14",{"kind":159,"url":142,"label":8},"darooyab",{"pregnancy":161,"lactation":170,"pediatric":178,"geriatric":186},{"level":162,"text":163,"quote":166,"refs":167},"caution",{"fa":164,"en":165},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Neonates whose mothers are exposed to antipsychotic drugs, including FANAPT, during the third trimester of pregnancy are at risk for extrapyramidal and\u002For withdrawal symptoms following delivery [see Clinical Considerations ] .",[168],{"source":33,"section":169},"8.1",{"level":162,"text":171,"quote":174,"refs":175},{"fa":172,"en":173},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information regarding the presence of iloperidone or its metabolites in human milk, the effects of iloperidone on a breastfed child, nor the effects of iloperidone on human milk production.",[176],{"source":33,"section":177},"8.2",{"level":162,"text":179,"quote":182,"refs":183},{"fa":180,"en":181},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of FANAPT have not been established in pediatric patients.",[184],{"source":33,"section":185},"8.4",{"level":187,"text":188,"quote":191,"refs":192},"avoid",{"fa":189,"en":190},"برچسب: در سالمندان هشدار جدی یا پرهیز.","Label: serious warning or avoid in older adults.","Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.",[193],{"source":33,"section":109},{"kind":195,"refs":196,"id":147},"NDA",[197],{"source":33,"section":198},"SPL approval \u002F marketing category",1792191548833]